(Press-News.org) A team of research scientists from VTT Technical Research Centre of Finland, the University of Turku and the University of Eastern Finland has discovered a previously unknown Cent-1 molecule that kills cancer cells. Their research also shows that new cancer drug candidates can be identified faster and at lower cost by using computer-assisted and cell-based screening of compounds.
The objective of the research project led by Marko Kallio, Principal Scientist at VTT, was to accelerate the drug development process by identifying new compounds that would possess similar binding properties and cellular phenotype , but a different chemical structure, as the selected drugs in clinical use or investigational compounds in development.
The scientists combined computer-based screening and cell-based assays to create a method that can significantly accelerate drug discovery and thereby lower development costs. It is highly likely that the new compounds identified using this method have not yet been patented.
The research team conducted a computer-assisted screening of 65,000 compounds and cell-based assays on the 150 highest scoring hit compounds, before identifying the Cent-1 molecule. The Cent-1 molecule kills cancer cells through a mechanism similar to that of the template drug Rigosertib that is currently under commercial development. However, since the chemical structure of the Cent-1 compound differs from Rigosertib, there are no major obstacles to further development.
What makes the study also significant is evidence that Rigosertib did not inhibit its reported target genes; there is reason to believe that the drug has a different mechanism of action at molecular level than anticipated. This drug discovery related study was published in the Molecular Cancer Therapeutics in April 2014.
Development of new drugs is an expensive and time-consuming process. It usually takes around 10 years to complete and costs several hundreds of millions of euros. In addition, risks associated with the usability, therapeutic efficacy and market share of medicinal substances are usually realised only in the final stages of drug development.
INFORMATION:
Further information:
VTT Technical Research Centre of Finland
Marko Kallio, Principal Scientist
Tel. +358 20 722 2810
marko.kallio@vtt.fi
Further information on VTT:
Olli Ernvall
Senior Vice President, Communications
358 20 722 6747
olli.ernvall@vtt.fi
http://www.vtt.fi
VTT Technical Research Centre of Finland
VTT is a leading multitechnological applied research organization in Northern Europe. VTT creates new technology and science-based innovations in co-operation with domestic and foreign partners. Every third Finnish technology innovation contains VTT expertise. VTT's turnover is EUR 310 million and its personnel totals 2,900.
Finnish researchers discovered a new anticancer compound
2014-05-21
ELSE PRESS RELEASES FROM THIS DATE:
Personalizing revascularization strategy for STEMI patients is vital, EuroPCR panel finds
2014-05-21
21 May 2014, Paris, France: A Great Debate at EuroPCR 2014 saw experts discussing the role of the two most valuable strategies to save the lives of ST-segment Elevation Myocardial Infarction (STEMI) patients: primary percutaneous coronary intervention (PCI) and thrombolysis.
Both these are effective treatments that actively save lives, and when there is no option for primary percutaneous coronary intervention, thrombolysis is the way to proceed, participants heard. The topic of the Great Debate, 'Primary PCI for STEMI: an emergency!' was selected ahead of the session ...
EuroPCR 2014 showcases technological advances in complex cardiovascular interventions
2014-05-21
St Jude Medical's Nanostim device and Medtronic's Micra, both single-chamber leadless pacing systems, and the most advanced commercially available valve, the Edwards Sapien 3 Transcatheter Heart Valve (Edwards Life Sciences) featured in the discussions.
With regard to leadless pacing, participants heard that there was a need for a novel system that provides reliable pacing and sensing, and addresses the challenges of current pacing systems by minimising the risks of infection, pneumothorax, dislodgement and long-term infection.
Prof Panos Vardas, University Hospital ...
Laser light needs more bass
2014-05-21
They shed light on atomic and molecular processes: ultrashort laser pulses are required to study extremely fast quantum phenomena. For years, scientists have been trying to tune the shape of light waves so as to, for instance, steer an electron on exactly the right path. At the TU Vienna, an extraordinarily powerful new method to influence the shape of the laser light wave has been developed in cooperation with the Imperial College in London and the Max-Born-Institute in Berlin. Much like the characteristic sound of a musical instrument, which results from the combination ...
Research breakthrough paves the way for understanding serious diseases
2014-05-21
A few years ago researchers described a Turkish family whose family members moved around on all fours. It turned out that they lacked the sense of equilibrium. This was caused by the rare neurological disease CAMRQ, which is the result of a mutation in the lipid pump in the cells. On the other hand, it was not known why the genetic error had such serious consequences.
The discovery provided inspiration for a Danish study of the mechanism for the vital lipid pump function, the so-called flippase, which transports lipids in the membrane that surrounds every single cell ...
Dolutegravir in HIV-1 infection: Added benefit in adult patients
2014-05-21
Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) now examined whether the new drug offers an added benefit over the appropriate comparator therapy.
The dossier compiled by the drug manufacturer provided proof of a considerable added ...
EORTC to present cancer research results at ASCO 2014
2014-05-21
The EORTC will present nine abstracts at the ASCO 2014 Annual Meeting which will be held 30 May – 03 June 2014 in Chicago, Illinois. Four abstracts will be presented in Oral Abstract Sessions, one in a Poster Highlights Session, and another four in General Poster Sessions.
Oral Abstract Sessions
Abstract # 4500
Monday, 02 June, 9:45 – 9:57, E Hall D1
Cora N. Sternberg, Iwona Skoneczna, J.M.Kerst, Sophie Fossa, Peter Albers, Mads Agerbaek, Herlinde Dumez, Maria De Santis, Christine Theodore, Michael Leahy, J.D. Chester, Antony Verbaeys, Armelle Caty, Gedske Daugaard, ...
The Net Children Go Mobile Project launches its report at the ICA 64th Annual Conference
2014-05-21
Washington, DC (May 21, 2014) The Net Children Go Mobile project will release new data on children's mobile use at the 64th Annual Conference of the International Communication Association at the Seattle Sheraton hotel. The project found that 46% of children own a smartphone and 41% use it daily to go online, while 20% own a tablet but 23% use it on a daily basis to access the Internet. Smartphone and tablet users engage more in communication and entertainment activities. They also have a higher level of digital skills, safety skills, and communicative abilities. However, ...
A star cluster in the wake of Carina
2014-05-21
NGC 3590 is a small open cluster of stars around 7500 light-years from Earth, in the constellation of Carina (The Keel). It is a gathering of dozens of stars loosely bound together by gravity and is roughly 35 million years old.
This cluster is not just pretty; it is very useful to astronomers. By studying this particular cluster — and others nearby — astronomers can explore the properties of the spiral disc of our galaxy, the Milky Way. NGC 3590 is located in the largest single segment of a spiral arm that can be seen from our position in the galaxy: the Carina spiral ...
Study shows iron from melting ice sheets may help buffer global warming
2014-05-21
A newly-discovered source of oceanic bioavailable iron could have a major impact our understanding of marine food chains and global warming. A UK team has discovered that summer meltwaters from ice sheets are rich in iron, which will have important implications on phytoplankton growth. The findings are reported in the journal Nature Communications on 21st May, 2014*.
It is well known that bioavailable iron boosts phytoplankton growth in many of the Earth's oceans. In turn phytoplankton capture carbon – thus buffering the effects of global warming. The plankton also feed ...
More maternal mental health surveillance is needed, suggests new study
2014-05-21
Maternal depression is more common at four years following childbirth than at any other time in the first 12 months after childbirth, and there needs to be a greater focus on maternal mental health, suggests a new study published today (21 May) in BJOG: An International Journal of Obstetrics and Gynaecology.
The study using data from 1507 women from six public hospitals in Melbourne, Australia, examines the prevalence of maternal depression from early pregnancy to four years postpartum. The researchers identify the possible risk factors for depressive symptoms at four ...